NCT05969184 2023-08-01
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
Peking University Cancer Hospital & Institute
Phase 2 Unknown
Clinical Trials
3 trialsNCT05577442 2022-10-19
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05244993 2022-07-12
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown